Novoprotein(SH:688137)2024-06-13 07:38Group 1: Financial Performance - The company reported a slowdown in regular business and significant changes in sales structure during Q1 2024 [3] - There was no unconventional revenue from COVID-19 related products in Q1 2024 [4] - The company aims to maintain revenue growth despite challenges from macroeconomic policy adjustments and industry fluctuations [4] Group 2: Research and Development - The company is increasing R&D investment and integrating 7 comprehensive technology platforms and 23 core technologies [4] - Focus areas include cutting-edge life sciences, particularly in NGS, AI, and synthetic biology [4] - The company is committed to developing innovative products and enhancing its service offerings across various fields [4] Group 3: Product Portfolio - Core products include target and factor proteins, recombinant antibodies, and mRNA raw materials and reagents [5] - mRNA technology is expanding in applications such as infectious disease vaccines and cancer vaccines, but has not yet reached industrialization [5] - The company provides customized technical services and technology transfer primarily for research institutions and pharmaceutical companies [5] Group 4: ESG and Governance - The company is focused on improving its ESG rating and governance structure, with certifications like ISO9001:2015 and ISO13485:2016 [6] - There is an ongoing commitment to environmental protection and social responsibility [6] Group 5: Market Expansion - The company is actively expanding its overseas market presence and sales channels [6] - Efforts are being made to enhance marketing networks to boost international sales revenue [6]